PharmaEngine, Inc. and Sentinel Oncology Limited enter into an exclusive collaboration and license agreement for SOL-578, a Chk1 inhibitor ... Dec 04
The EMA grants orphan status to medicinal products intended to treat rare disorders that affect fewer than 5 people per 10,000 in the European ... Dec 04
Zydus Cadila, had received an approval from the Drugs Controller General of India to start the Phase 3 clinical trial in COVID-19 patients with ... Dec 04
Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts... Dec 04
-Advertisements-